Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2001-01-31
2009-11-03
Chen, Shin-Lin (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093210, C435S320100, C435S455000, C536S023500
Reexamination Certificate
active
07612046
ABSTRACT:
The present invention relates to a cellular therapy of renal failure, i.e. preventing, delaying, and treating acute/chronic renal failure via the use of an effective dose of a substance capable of inducing and/or enhancing Pax2 expression in a mammal for the preparation of a pharmaceutical composition for treating, preventing or delaying a renal dysfunction/failure in a mammal. Additionally, the present invention provides for a method for converting mesenchymal tissue into an epithelial tissue comprising the administration of an effective amount of a substance capable of inducing and/or enhancing Pax2 expression in mesenchymal tissue and for a method for the regeneration of renal stem cells comprising the administration of an effective amount of a substance capable of inducing and/or enhancing Pax2 expression.
REFERENCES:
patent: 5360790 (1994-11-01), Humes
patent: 5750495 (1998-05-01), Woo
patent: 5882923 (1999-03-01), Sariola et al.
patent: 2003/0092657 (2003-05-01), Goodyer et al.
patent: 0 853 942 (1999-07-01), None
patent: WO 98/41227 (1998-09-01), None
patent: WO 98/50060 (1998-11-01), None
Anglani et al. (2004) In search of adult renal stem cells. J. Cell. Mol. Med. 8:474-487.
Sandall. (2000) Genes and Gene Expression. Clin. Orth. and Rel. Res. 379S:S9-S16.
Zhang et al. (2004) Angiotensin II stimulates Pax-2 in rat kidney proximal tubular cells: Impact on proliferation and apoptosis.
Daniel et al. (2001) Pax-2 expression in Adult renal Tumors. 32:282-287.
Tavassoli et al. (1997) Alternative splicing in Pax2 generates a new reading frame and an extended conserved coding region at the carboxy terminus. Hum Genet. 101:371-375.
Abbattista et al. (2004) Stem Cells and Kidney diseases. Minerva Medica. 95:411-8.
Johnson-Saliba et al. (2001) Gene Therapy:optimising DNa delivery to the nucleus. Curr. Drug Targets 2:371-99.
Verma et al., Gene therapy-promises, problems and prospects. (1997) Nature. 389:239-242.
Ritz-Laser et al. (2000) The paired homeodomain transcription Factor Pax-2 is expressed in the endocirine pancreas and transactivates the glucagon gene promoter. J. Biol. Chem. 275:32708-32715.
Hopes Glossary (2005) R. pp. 1-4. Http://www.stanford.edu/group/hopes/sttools/gloss/r.html.
Shoji et al. (2004) Current Status of Delivery systems to improve Target Efficacy of Oligonucleotides. Curr. Pharm. Design 10:785-796.
Pfeifer and Varmus (2001) Gene Therapy: Promises and Problems Annu. Rev. Genomics Hum. Genet. 2:177-211.
Greco et al. (2002) Cancer Gene therapy:‘Delivery, Delivery, Delivery’. Frontiers in Bioscience. 7:d1516-1524.
Yokoo et al. (2003) Stem Cell Gene Therapy for Chronic Renal Failure. Curr. Gene Therapy. 3:387-394.
Deonarain, M., 1998, Expert Opin. Ther. Pat., vol. 8, pp. 53-69.
Verma et al., Sep. 1997, Nature, vol. 389, pp. 239-242.
Eck et al., 1996, Goodman & Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, p. 77-101.
Gorecki, D., 2001, Expert Opin. Emerging Drugs, 6(2): 187-198.
Rudinger, 1976, Peptide Hormones, Parsons, University Park Press, Baltimore, p. 1-7.
Kaye et al., 1990, Proc. Natl. Acad. Sci. USA, vol. 87, pp. 6922-6926.
Skolnick et al., 2000, Trends in Biotech, vol. 18, p. 34-39.
McConnell et al., 1997, Oncogene, vol. 14, p. 2689-2700.
Luo et al., “BMP-7 is an inducer of nephrogenesis and is also required for eye development and skeletal patterning,”Genes 7 Development(1995), vol. 9, No. 22, pp. 2808-2820, SP001015455, ISSN: 0890-9369.
Cale et al., “Tumor necrosis factor-alpha inhibits epithelial differentiation and morphogenesis in the mouse metanephric kidney in vitro,”International Journal of Developmental Biology(Jul. 1998), vol. 42, No. 5, pp. 663-674, XP001015477, ISSN: 0214-6282.
Eccles, “The role of Pax2 in Normal and Abnormal Development of the Urinary Tract,”Pediatric Nephrology(1998), vol. 12, No. 9, pp. 712-720, XP001009818, ISSN: 0931-041X, Springer Verlag, Berlin, Germany.
Imgrund et al., “Re-expression of the developmental gene Pax-2 during expreimental acute tubular necrosis in mice,”Kidney International(Oct. 1999), vol. 56, No. 4, pp. 1423-1431, XP002174276, ISSN: 0085-2538.
Barasch et al., “Mesenchymal to epithelial conversion in rat metanephros is induced by LIF,”Cell(Nov. 12, 1999), vol. 99, No. 4, pp. 377-386, XP002174277, ISSN: 0092-8674.
Herzlinger et al., “Wnt-1 and Wnt-2 are potent inducers of nephrogenesis,”FASEB Journal(1994), vol. 8, No. 4-5, p. A822, XP00217428, ISSN: 0892-6638.
Stark et al., “Epithelial transformation of metanephric mesenchyme in the developing kidney regulated by Wnt-4,”Nature(Dec. 15, 1994), vol. 372, No. 6507, pp. 679-683, XP002130718, ISSN: 0028- 0836, MacMillan Journals Ltd., London, Great Britain.
Torban et al., “Effects of PAX2 Expression in a Human Fetal Kidney (HEK293) Cell Line,”Biochimica Et Biophysica Acta(1998), vol. 1401, pp. 53-62, XP001009827, ISSN: 0006-3002, Amsterdam, Netherlands.
Davies et al., “Induction of early stages of kidney tubule differentiation by lithium ions,”Developmental Biology(1995), vol. 167, No. 1, pp. 50-60, XP001015458, ISSN: 0012-1606.
Padanilam et al., “Insulin-like growth factor I-enhanced renal expression of ostenpontin after acute ischemic injury in rats,”Endocrinology(1996), vol. 137, No. 5, pp. 2133-2140, XP001015470, ISSN: 0013-7227.
Basile et al., “Expression of bcl-2 and bax in regenerating rat renal tubules following ischemic injury,”American Journal of Physiology(1997), vol. 272, No. 5, part 2, pp. F640-F647, XP001015457, ISSN: 002-9513.
Dressler et al., “Pax-2 is a DNA-binding protein expressed in embryonic kidney and Wilms tumor”, Proc. Natl. Acad. Sci., USA, vol. 89, pp. 1179-1183, Feb. 1992 (Developmental Biology).
Cai et al., “Groucho suppresses Pax2 transactivation by inhibition of JNK-mediated phosphorylation”, The EMBO Journal, Vo. 22, No. 20, pp. 5522-5529, 2003.
(Abstract) Humes et al., “Tubulogenesis from isolated single cells of adult mammalian kidney: clonal analysis with a recombinant retrovirus”, Am. J. Physiol., Jul. 1996, 271, F42-9).
(Abstract) Tavassoli et al., “Alternative splicing in PAX2 generates a new reading frame and an extended conserved coding region at the carboxy terminus”, Hum Genet. Dec. 1997: 101(3):371-5.
(Abstract) Havik et al., “A novel paired domain DNA recognition motif can mediate Pax2 repression of gene transcription” Biochem Biophys Res Commun. Dec. 20, 1999, 266(2):532-41.
Chan et al., (2005) Tubular expression of angiotensin II receptors and their regulation in IgA nephropathy. J Am Soc Nephrol 16, 2306-17.
Havik et al., Biochem Biophys Res Commun Dec. 20, 1999:266(2):532-41.
Humes et al., Am J. Physiol., Jul. 1996:(271(1 Pt 2):F42-9.
Zhang et al., (2004b) Angiotensin II stimulates Pax-2 in rat kidney proximal tubular cells: impact on proliferation and apoptosis. Kidney Int 66, 2181-2192.
Zhang et al., JR (2004a) Angiotensin II increases Pax-2 expression in fetal kidney cells via the AT2 receptor. J Am Soc Nephrol 15, 1452-1465.
Imgrund Michael Carl Elmar
Rothenpieler Uwe Waldemar
Chen Shin-Lin
Foley & Lardner LLP
LandOfFree
Method for treating kidney disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating kidney disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating kidney disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4056348